Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 11/20 | 0.60 |
| ▸ | BCL2 | P10415 | 11/20 | 0.60 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.53 |
| ▸ | FGFR1 | P11362 | 7/20 | 0.45 |
| ▸ | FLT1 | P17948 | 1/20 | 0.44 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14935532 | 0.86 | MCL1 (0.54) | MCL1BCL2BCL2L1FGFR1FLT1 | |
| SCHEMBL14949237 | 0.85 | MCL1 (0.71) | MCL1BCL2BCL2L1FGFR1FLT1 | |
| SCHEMBL2367640 | 0.81 | MCL1 (0.67) | MCL1BCL2BCL2L1FGFR1FLT1 | |
| SCHEMBL2367939 | 0.81 | MCL1 (0.88) | MCL1BCL2BCL2L1FGFR1 | |
| SCHEMBL2367447 | 0.81 | MCL1 (0.88) | MCL1BCL2BCL2L1FGFR1 | |
| SCHEMBL14935533 | 0.80 | MCL1 (0.41) | MCL1BCL2BCL2L1FGFR1FLT1 | |
| SCHEMBL14935455 | 0.78 | BCL2 (0.48) | MCL1BCL2FGFR1FLT1FGFR3 | |
| SCHEMBL14935299 | 0.76 | MCL1 (0.52) | MCL1BCL2BCL2L1FGFR1FLT1 | |
| SCHEMBL2527574 | 0.74 | MCL1 (0.51) | MCL1BCL2BCL2L1 | |
| SCHEMBL2528631 | 0.74 | MCL1 (0.51) | MCL1BCL2BCL2L1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10195213-B2 | Chemical entities that kill senescent cells for use in treating age-related disease | UNITY BIOTECHNOLOGY, INC. (US) | 2019-02-05 | — | — | US | disclosed |
| US-20170281649-A1 | COMPOUNDS AND THERAPEUTIC USES | UNITY BIOTECHNOLOGY, INC. | 2017-10-05 | — | — | US | disclosed |
| US-20110251188-A1 | ACENAPHTHO HETEROCYCLE COMPOUNDS, CYCLODEXTRIN INCLUSION COMPOUNDS AND COMPLEXES, AND USES IN THE MANUFACTURES OF BH3 PROTEIN ANALOGUE, BCL-2 FAMILY PROTEIN INHIBITORS THEREOF | DALIAN UNIVERSITY OF TECHNOLOGY (CN) | 2011-10-13 | — | — | US | disclosed |
| EP-2366701-A1 | ACENAPHTHO HETEROCYCLE COMPOUNDS, CYCLODEXTRIN INCLUSION COMPOUNDS AND COMPLEXES, AND USES IN THE MANUFACTURES OF BH3 PROTEIN ANALOGUE, BCL-2 FAMILY PROTEIN INHIBITORS THEREOF | Dalian University Of Technology (CN) | 2011-09-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170281649-A1 | COMPOUNDS AND THERAPEUTIC USES | TP53, NQO1, SHMT2 | MCL1 137/4885BCL2 520/4885BCL2L1 953/4885 |
| US-20110251188-A1 | ACENAPHTHO HETEROCYCLE COMPOUNDS, CYCLODEXTRIN INCLUSION COMPOUNDS AND COMPLEXES, AND USES IN THE MANUFACTURES OF BH3 PROTEIN ANALOGUE, BCL-2 FAMILY PROTEIN INHIBITORS THEREOF | BID, BCL2, BAX | MCL1 10/4885BCL2 2/4885BCL2L1 4/4885 |
| US-10195213-B2 | Chemical entities that kill senescent cells for use in treating age-related disease | TP53, CDKN1A, GLA | MCL1 8/4885BCL2 132/4885BCL2L1 464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.